Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Terumo: Double-digit Growth in Consolidated Sales, Profits
November 13, 2006
- Baxter to Provide Plasma/Albumin-Free Factor VIII to Hemophilia A Patients in Japan
November 13, 2006
- MEDICAL DEVICE NEWS IN BRIEF
November 13, 2006
- Eisai: Major Products Contribute to Strong Growth in 1st Half
November 13, 2006
- Roche Diagnostics' ACCU-CHEK Aviva Awarded Good Design Prize
November 13, 2006
- Kyowa Hakko: Consolidated Sales Down 2.4%
November 13, 2006
- Korosho to Build Nationwide Clin. Trial Network by Therapeutic Field
November 13, 2006
- Torii: NHI Price Revision, GE Competition Hit Sales, Profits
November 13, 2006
- Off-label Use Points Up Weakness of Domestic Clin. Research: Mr Sato
November 13, 2006
- Asahi Kasei Pharma: Profits Up Despite Decline in Sales
November 13, 2006
- R&D NEWS IN BRIEF
November 13, 2006
- Signa HDe, BrightSpeed Granted Good Design Awards: GE Yokogawa Medical System
November 6, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 6, 2006
- Call for Withdrawal from JPA Gathers Momentum among JACDS Members
November 6, 2006
- SEMINAR
November 6, 2006
- Import of Fludara Tab Recommended for Approval
November 6, 2006
- One Year Needed to Complete Merger with Schering: Mr Eiki of Bayer
November 6, 2006
- REGULATORY NEWS IN BRIEF
November 6, 2006
- Eisai Completes Acquisition of 4 Oncology-Related Products from Ligand
November 6, 2006
- Proteins Predict Necessity of Lung Cancer Adjuvant Therapy
November 6, 2006
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…